Drug Profile
AV 412
Alternative Names: AV-412; MP-412Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer AVEO Pharmaceuticals
- Class Antineoplastics; Piperazines; Quinazolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 20 Jul 2010 Discontinued - Phase-I for Solid tumours in Argentina (PO)
- 20 Jul 2010 Discontinued - Phase-I for Solid tumours in Spain (PO)
- 20 Jul 2010 Discontinued - Phase-I for Solid tumours in USA (PO)